Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 124, Issue 1, 2006, Pages 70-76

  Ferrari, B ^a   Pezzuto, A ^a   Barusi, L ^a   Coppola, F ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Controlled ovarian hyperstimulation; GnRH antagonist; LH; VEGF

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LEUPRORELIN; LUTEINIZING HORMONE; PROSTAGLANDIN E2; VASCULOTROPIN;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN RELEASE; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY FOLLICLE FLUID; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL SIGNIFICANCE;

EID: 29644435311     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2005.08.017     Document Type: Article

References (50)

1. L.P. Cheung, P.M. Lam, and I.H. Lok GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial Hum Reprod 20 2005 616 621
2. M.A. Akman, H.F. Erden, S.B. Tosun, N. Bayazit, E. Aksoy, and M. Bahceci Addition of GnRH antagonist in cycles of poor responders undergoing IVF Hum Reprod 15 2000 2145 2147
3. S.J. Fasouliotis, N. Laufer, S. Sabbagh-Ehrlich, A. Lewin, A. Hurwitz, and A. Simon Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF J Assist Reprod Genet 20 2003 455 460
4. European and Middle East Orgalutran Study Group Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation Hum Reprod 16 2001 644 651
5. C. Albano, R.E. Felberbaum, and J. Smitz Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group Hum Reprod 15 2000 526 531
6. G. Borm, and B. Mannaerts Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group Hum Reprod 15 2000 1490 1498
7. H. Al-Inany, and M. Aboulghar GnRH antagonist in assisted reproduction: a Cochrane review Hum Reprod 17 2002 874 885
8. E.R. Hernandez Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists Hum Reprod 15 2000 1211 1216
9. S. Kol Embryo implantation and GnRH antagonists: GnRH antagonists in ART: lower embryo implantation? Hum Reprod 15 2000 1881 1882
10. N. Ferrara, K. Houck, L. Jakeman, and D.W. Leung Molecular and biological properties of the vascular endothelial growth factor family of proteins Endocr Rev 13 1992 18 32
11. K. Gupta, S. Kshirsagar, and W. Li VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling Exp Cell Res 247 1999 495 504
12. N. Ferrara, and T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
13. E. Geva, and R.B. Jaffe Role of vascular endothelial growth factor in ovarian physiology and pathology Fertil Steril 74 2000 429 439
14. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J 13 1999 9 22
15. N.A. Klein, D.E. Battaglia, and T.K. Woodruff Ovarian follicular concentrations of activin, follistatin, inhibin, insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-2 (IGFBP-2), IGFBP-3, and vascular endothelial growth factor in spontaneous menstrual cycles of normal women of advanced reproductive age J Clin Endocrinol Metab 85 2000 4520 4525
16. World Health Organization WHO laboratory manual for the examination of human semen and sperm-cervical mucus interaction 3rd ed. 1992 Cambridge University Press Cambridge, UK p. 1-107
17. W. Risau Mechanism of angiogenesis Nature 386 1997 671 674
18. P.D. Taylor, S.G. Hillier, and H.M. Fraser Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary J Endocrinol 183 2004 1 17
19. J.C. Chavez, and J.C. LaManna Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1 J Neurosci 15 2002 8922 8931
20. M.G. Slomiany, and S.A. Rosenzweig Autocrine effects of IGF-1 induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19 Am J Physiol Cell Physiol 287 2004 C746 C753
21. J.A. Forsythe, B.H. Jiang, and N.V. Iyer Activation of vascular growth factor gene transcription by hypoxia-inducible factor 1 Mol Cell Biol 16 1996 4604 4613
22. G. Basini, F. Bianco, F. Grasselli, M. Tirelli, S. Bussolati, and C. Tamanini The effects of reduced oxygen tension on swine granulosa cell Regul Pept 120 2004 69 75
23. C.I. Friedman, D.B. Seifer, E.A. Kennard, L. Arbogast, B.M. Alak, and D.R. Danforth Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential Fertil Steril 70 1998 836 839
24. C. Battaglia, A.D. Genazzani, G. Regnani, M.R. Primavera, F. Petraglia, and A. Volpe Perifollicular Doppler flow and follicular fluid vascular endothelial growth factor concentrations in poor responders Fertil Steril 74 2000 809 812
25. P. Ocal, S. Aydin, and I. Cepni Follicular fluid concentrations of vascular endothelial growth factor, inhibin A and inhibin B in IVF cycles: are they markers for ovarian response and pregnancy outcome? Eur J Obstet Gynecol Reprod Biol 115 2004 194 199
26. G. Barroso, M. Barrionuevo, and P. Rao Vascular endothelial growth factor, nitric oxide, and leptin follicular fluid levels correlate negatively with embryo quality in IVF patients Fertil Steril 72 1999 1024 1026
27. C.I. Friedman, D.R. Danforth, C. Herbosa-Encarnacion, L. Arbogast, B.M. Alak, and D.B. Seifer Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction Fertil Steril 68 1997 607 612
28. R. Quintana, L. Kopcow, G. Marconi, C. Sueldo, G. Speranza, and R.I. Barañao Relationship of ovarian stimulation response with vascular endothelial growth factor and degree of granulosa cell apoptosis Hum Reprod 16 2001 1814 1818
29. N. Doldi, M. Bassan, P.M. Fusi, and A. Ferrari In controlled ovarian hyperstimulation, steroid production, oocyte retrieval, and pregnancy rate correlate with gene expression of vascular endothelial growth factor J Assist Reprod Genet 14 1997 589 592
30. N. Doldi, A. Destefani, A. Gessi, D. Grossi, and A. Ferrari Human albumin enhances expression of vascular endothelial growth factor in cultured human luteinizing granulosa cells: importance in ovarian hyperstimulation syndrome Hum Reprod 14 1999 1157 1159
31. J. Van Blerkom, M. Antczak, and R. Schrader The developmental potential of the human oocyte is related to the dissolved oxygen content of follicular fluid: association with vascular endothelial growth factor levels and perifollicular blood flow characteristics Hum Reprod 12 1997 1047 1055
32. J.A. Garcia-Velasco, V. Isaza, C. Vidal, A. Landazabal, J. Remohi, C. Simon, and A. Pellicer Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix) Hum Reprod 16 2001 2533 2539
33. J.S. Richards Maturation of ovarian follicles: actions and interactions of pituitary and ovarian hormones on follicular cell differentiation Physiol Rev 60 1980 51 89
34. B. Acevedo, M. Sanchez, J.L. Gomez, J. Cuadros, E. Ricciarelli, and E.R. Hernandez Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles Fertil Steril 82 2004 343 347
35. J. Tesarik, and C. Mendoza Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence Hum Reprod 17 2002 3129 3137
36. C.M. Reilly, W.E. Cannady, V.B. Mahesh, V.S. Stopper, L.M. De Sevilla, and T.M. Mills Duration of estrogen exposure prior to FSH stimulation critical to granulosa cell growth and differentiation in rats Biol Reprod 54 1996 1336 1343
37. B. Oussaid, P. Lonergan, and H. Khatir Effect of GnRH antagonist-induced prolonged follicular phase on follicular atresia and oocyte developmental competence in vitro in superovulated heifers Reprod Fertil 118 2000 137 144
38. M.C. Rao, A.R.J. Midgley, and J.S. Richards Hormonal regulation of ovarian cellular proliferation Cell 14 1978 71 78
39. K. Bogovich, and J.S. Richards Androgen biosynthesis in developing ovarian follicle: evidence that luteinizing hormone regulates theca 17α-hydroxylase and C17-20 lyase activity Endocrinology 111 1982 1201 1208
40. J. Tesarik, and C. Mendoza Nongenomic effects of 17 beta-estradiol on maturing human oocytes: relationship to oocyte developmental potential J Clin Endocrinol Metab 80 1995 1438 4143
41. Y. Yoshimura, and E.E. Wallach Studies of mechanism(s) of mammalian ovulation Fertil Steril 47 1987 22 34
42. M. Filicori The potential value of mid-follicular phase LH Hum Reprod 17 2002 517 518
43. R. Fleming, F. Lloyd, M. Herbert, J. Fenwick, T. Griffiths, and A. Murdoch Effects of rofound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone Hum Reprod 13 1998 1788 1792
44. L.G. Westergaard, S.B. Laursen, and C.Y. Andersen Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction Hum Reprod 15 2000 1003 1008
45. B. Ferrari, L. Barusi, M. Lanna, and F. Coppola Ovarian response and pregnancy outcome related to midfollicular LH levels in down-regulated women undergoing assisted reproduction Reprod Med 49 2004 148 152
46. Ganirelix Dose-finding Study Group A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon) Hum Reprod 3 1998 3023 3031
47. V.Y. Fujimoto, S.E. Monroe, L.R. Nelson, D. Downey, and R.B. Jaffe Dose-related suppression of serum luteinizing hormone in women by a potent new gonadotrophin-releasing hormone antagonist (Ganirelix) administered by intranasal spray Fertil Steril 67 1997 469 473
48. J.A. Huirne, A.C. van Loenen, and R. Schats Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy Hum Reprod 20 2005 359 367
49. E.M. Kolibianakis, K. Zikopoulos, J. Schiettecatte, J. Smitz, H. Tournaye, M. Camus, A.C. Van Steirteghem, and P. Devroey Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF Reproduction 19 2004 2490 2496
50. F. Coppola, E. Potì, B. Ferrari, L. Barusi, M.C. Salvarani, and E. Vadora Profound luteinizing hormone suppression induces deleterious follicular environment during assisted reproduction technology Fertil Steril 79 2003 459 460